Call for Abstracts


1. Abstract Submission

All submissions for theme sessions and general presentations must be made online through the congress website.
Please click the “New Submission” button at the bottom of this page.

For submissions from Japan, please refer to the Japanese page:
https://www.convention-plus.jp/111jges/endai

2. Submission Period

◯ General Abstract Submission Period
September 24 (Wed), 2025, 13:00 – November 5 (Wed), 2025, 18:00 (JST)

◯ Invited Presentations:
Speakers who have been invited by the 111JGES Congress Secretariat will receive a separate notification.

3. Requirements

1. The content of the presentation must not have been previously presented at this Society or at any other academic society in Japan.

2. No conflict with ethical regulations
Research involving human-derived samples or data must comply with the Declaration of Helsinki. Please ensure that approval from an ethics committee and informed consent are obtained. If the Editorial Board suspects ethical issues, the matter will be referred to the Ethics Committee of this Society. To protect personal privacy, images or data that may identify individuals must not be included.

3. Conflict of Interest(COI)
All authors must confirm and disclose conflicts of interest at the time of submission. Please also refer to the COI Declaration Guidelines.

Guidelines Regarding Conflicts of Interest (COI) in Medical Research
Detailed Rules Regarding Conflicts of Interest (COI) in Medical Research

4. The conference proceedings will be available through an app for smartphones and tablets. Please note that accepted abstracts will be electronically published.

5. The same department/institution may not submit multiple abstracts on the same subject with different first authors. In such cases, both submissions will be withdrawn. However, if the first authors belong to different institutions, co-authorship is permitted. For multi-institutional studies, please indicate this clearly in the title (e.g., by listing the study group name).

6. You cannot submit the same contents in different categories. Abstracts considered to be the same will be discussed by the reviewers and program committee. Please note that when the abstracts are judged to be identical, both will be rejected. For categories, please see 5. Categories and Presentation type.

7. Withdrawal and absence
If the first author is unable to give the presentation due to unavoidable circumstances, only a co-author will be permitted to present on their behalf. In such cases, the achievement shall, in principle, be regarded as belonging to the first author. However, by submitting a waiver form prescribed by the society, the first author may transfer the rights to the co-author who gives the presentation.

4. Eligibility

• The first and co-authors must be members of JGES.
• However, for submissions from overseas, non-members may also apply.
• In case of non-members (including non-physicians such as pathologists or biostatisticians who contributed to the research), they may be included as co-authors.

5. Presentation Type & Categories

●Presentation type　*Please choose one.
01. Apply for theme sessions: Withdraw the abstract if not accepted
02. Apply for theme sessions: Oral Presentation if not accepted
03. Apply for theme sessions: Poster Presentation if not accepted
04. Apply for theme sessions: Oral or Poster（Either Presentation）if not accepted
05. Oral Presentation preferred
06. Poster Presentation preferred
07. Oral or Poster （Either Presentation）

*If you choose "01. Abstract submission: Withdraw the abstract if not accepted", up to two co-authors can be registered.
*If you select "02. to 04. Apply for theme sessions: if not accepted": please be sure to select numbers 1 and 2 in the "Presenter’s order" column for the co-authors to be listed in the abstract book if your abstract is accepted. Please note if you do not select the order of presenters, co-authors 1 and 2 will be listed.

●Presentation Language
English on abstract, presentation slides, presentation and discussion

●Theme Sessions

■Theme Session General

General 1 Symposium　*English Session
Advancing AI in Endoscopic Practice: Current Status, Challenges, and Future Directions

Moderators：
Yutaka Saito, National Cancer Center Hospital, Endoscopy Division）
Masashi Misawa, Showa University Northern Yokohama Hospital, Digestive Disease Center）

Special Remarks：Mitsuru Kaise, Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine

>>Introduction

The rapid growth of large language models (LLMs) is bringing significant changes to our daily lives. In the field of gastrointestinal endoscopy, AI-powered products have already been approved and launched for both upper and lower GI applications. In recent years, their clinical usefulness has also begun to be reported. However, the impact of AI on education and human-AI interaction has not been sufficiently discussed. With the advancement of AI technologies, there have also been reports on AI-based risk stratification using pathological images, support for therapeutic endoscopy through segmentation techniques, and studies utilizing LLMs, showing a growing range of AI research related to endoscopy. In this session, we invite presentations on AI in endoscopic practice—whether already introduced into the market or not—to explore the current status, challenges, and the future potential of AI in this field.

■Theme Session Upper GI

Upper GI 5　Workshop　*English Session
Cutting-Edge of Endoscopic Resection for Esophageal and Gastric Neoplasms

Moderators:
Hajime Isomoto, Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University
Seiichiro Abe, Endoscopy Division, National Cancer Center Hospital
Keynote lecturer:　 Seiichiro Abe, Endoscopy Division, National Cancer Center Hospital

Commentator:　Hisashi Doyama, Department of Gastroenterology, Ishikawa Prefectural Central Hospital

Special remarks:　 Takashi Toyonaga, Division of Gastroenterology, Kobe University Graduate School of Medicine

>>Introduction

ESD is a minimally invasive, organ-preserving approach for treating superficial esophageal and early gastric cancers. Current guidelines recommend endoscopic resection as the standard of care, supported by favorable short- and long-term outcomes. However, ESD is still a technically demanding procedure with ongoing challenges in training, technical refinement, and managing adverse events. We look forward to discussions on future directions for refining the clinical indications for ESD and the criteria for curability assessment. These discussions will draw on high-quality clinical research and consider the needs of an aging population. We welcome submissions presenting innovative approaches to improving treatment outcomes, as well as highly relevant clinical studies of ESD/EMR (except EFTR). Outstanding submissions from outside Japan are also encouraged.

■Theme Session Lower GI

Lower GI 2　Workshop　*English Session
Current status and issues of endoscopic practice for inflammatory bowel disease (without inflammatory bowel disease associated neoplasia)

Moderators:
Ryota Hokari, Department of Internal Medicine, National Defense Medical College
Kenji Watanabe, Department of Internal Medicine for Inflammatory Bowel Disease, Toyama University

Commentator：　Fumihito Hirai, Faculty of Medicine School of Medicine, Fukuoka University

Special remarks:　Takayuki Matsumoto, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Iwate Medical University

>>Introduction

The progress in the management of inflammatory bowel diseases has been remarkable recently. This is not only due to launch of new drugs, but also to improvements in the level of practice, as represented by the treat-to-target strategy. While drug development is active, there are currently no outstanding medications. In this situation, endoscopic examination plays an important role by assessing treatment efficacy or deciding to switch the medications. In addition, small bowel endoscopy and endoscopic dilation are also important for Crohn's disease. Furthermore, histological remission in ulcerative colitis and transmural healing in Crohn's disease may become treatment goals in upcoming STRIDE III. In this session we call for abstracts, from a broad range of inflammatory bowel diseases including diseases other than ulcerative colitis and Crohn's disease, endoscopic approach from upper GI tract to the anus. We will discuss comprehensive consideration with endoscopy, including biomarkers and other imaging modalities. We look forward to receiving many ambitious abstracts.

Lower GI 4　Workshop　*English Session
New revolution of endoscopic diagnosis and treatment for colorectal tumors

Moderators:
Shoichi Saito, Lower GI Medicine Department, Cancer Institute Hospital of JFCR
Hiroaki Ikematsu, The University of Tokyo, The Institute of Medical Science

>>Introduction

Image-enhanced endoscopy (IEE) has long contributed to the standard for diagnosing gastrointestinal tumors endoscopically. Based on this technology, the JNET classification has been proposed for colorectal tumors and appears to be well established. Recently, endoscopic light sources shifted to LEDs (Light-Emitting Diode), enabling brighter images. New modalities have also been developed, such as TXI (Texture and Color Enhancement Imaging), RDI (Red Dichromatic Imaging), LCI (Linked Color Imaging), and ACI (Amber-red Color Imaging). We would like to introduce observation methods utilizing these latest modalities that are expected to improve diagnostic accuracy in endoscopic diagnosis, such as differentiation between tumors and non-tumors, and depth of invasion. Additionally, the development of endoscopic systems equipped with AI (artificial intelligence) using deep learning has made CADx (diagnosis) and CADe (detection) support possible, leading to changes in routine endoscopic examinations. The usefulness of these technologies is also a subject of discussion. On the other hand, ESD treatment is becoming standardized. This is due to the diversification of traction devices and the use of water or gel injection ESD techniques, among other advancements that have made treatment safer. We would like to discuss utilizing various techniques to further enhance the safety of endoscopic treatment. We look forward to receiving abstract submissions on endoscopic diagnosis and treatment utilizing the latest modalities.

■Theme Session Bile Duct and Pancreatis

Pancreatobiliary 1　Core session　Workshop　*English Session
The Role of Advanced Endoscopy in the Management of Inflammatory Digestive Diseases: Focus on Endoscopic Management of Acute Cholecystitis

Moderators:
Takao Itoi, Department of Gastroenterology and Hepatology, Tokyo Medical University
Hirofumi Kogure, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine

Previous report:　Koichiro Mandai , Gastroenterology, Japanese Red Cross Kyoto Daini Hospital

Special remarks:　Kazuo Inui, Gastroenterology, Medical corporation Yamashita Hospital

>>Introduction

The endoscopic management of acute cholecystitis is rapidly evolving, particularly for patients who are poor surgical candidates due to advanced age or comorbidities. Endoscopic transpapillary gallbladder drainage and endoscopic ultrasound-guided gallbladder drainage (EUS-GBD) have become effective, less invasive alternatives to percutaneous drainage. A recent milestone in Japan was the approval of lumen-apposing metal stents (LAMS) for the treatment of acute cholecystitis in high-risk surgical patients, reflecting growing recognition of the value of EUS-GBD. This session will highlight current endoscopic approaches, including indications, technical aspects, outcomes, and complications. We welcome submissions presenting clinical evidence, technical innovations, or critical perspectives aimed at improving the safety, efficacy, and long-term results of endoscopic treatment for acute cholecystitis.

Pancreatobiliary 2　Symposium　*English Session
Cutting edge of Interventional EUS

Moderators:
Ichiro Yasuda, Third Department of Internal Medicine, University of Toyama
Takuji Iwashita, Department of Gastroenterology, Shiga University of Medical Science

Commentator:
Masayuki Kitano, Second Department of Internal Medicine, Wakayama Medical University

Special remarks:　Mitsuhiro Kida, Endoscopy Center of Kitasato University Hospital

>>Introduction

Interventional EUS procedures, such as drainage of pancreatic fluid collections and the biliary duct, are now widely performed in clinical practice. Initially, interventional EUS procedures were performed using devices designed for ERCP-related procedures. The development of dedicated devices for EUS-guided procedures, a deeper understanding of these techniques, and the creation of various new techniques have made these procedures more stable and efficient. Furthermore, the application of various techniques through EUS-guided created routes or lumen-apposing metallic stents has expanded the indications. A diverse range of other EUS-guided interventions such as injection therapy, ablation therapy, implantation, and vascular interventions have also been reported. For this symposium, we invite submissions on a wide range of cutting-edge topics in interventional EUS. Please note that abstracts related to EUS-FNA are excluded from this symposium.

Pancreatobiliary 3　Panel Discussion　*English Session
Current status and future perspectives of biliary drainage

Moderators:
Kazuo Hara, Department of Gastroenterology, Aichi Cancer Center
Yousuke Nakai, Department of Internal Medicine, Institute of Gastroenterology, Tokyo Women's Medical University

Special remarks:　Naotaka Fujita, Director, Miyagi Medical Check-up Plaza

>>Introduction

Biliary drainage is essential for patients with malignant or benign biliary obstruction, bile duct stones, cholangitis, and bile leaks. While transpapillary drainage via ERCP remains the mainstay, EUS-guided biliary drainage (EUS-BD) is increasingly utilized in cases of difficult ERCP, and even as primary drainage. Since both ERCP and EUS-BD have their own advantages and limitations, and often complement each other, the choice of procedure should be tailored to each clinical scenario. Ongoing innovations and new devices also continue to emerge. At the same time, many important clinical questions remain, including the optimal choice of technique, device, and stent. In this session, we aim to discuss the current best practices and future perspectives of biliary drainage from multiple angles. We welcome abstracts covering all aspects of endoscopic biliary drainage, including early clinical experience with novel devices and small proof-of-concept studies.

●Categories and Presentation type
○Content category 1

01 Oral and oropharyngeal 06 Large intestine
02 Esophageal 07 Biliary
03 Gastric 08 Pancreatic
04 Duodenal 09 Hepatic
05 Small intestine 10 Other

○Content Categories 2
*Please choose your first and second preferences.

1 Neoplasm 18 Endoscopic hemostasis
2 Functional disease 19 Varicosis treatment
3 Infectious disease（Including H. pylori） 20 Emergency endoscopy
4 Inflammatory disease 21 Ultrathin endoscopes (including perinasal endoscopy)
5 Image management systems 22 Capsule endoscopy
6 Image analysis and processing 23 Intestinal endoscopy
7 Endoscope cleaning and disinfection 24 Gastrostomy
8 Pretreatment and perioperative management 25 Stents and dilation
9 Sedation 26 Laser treatment and PDT
10 Education and training 27 Diagnostic laparoscopy
11 Risk management (including elderly patients) 28 Laparoscopic surgery
12 Magnification, high-magnification, and image-enhancing endoscopy 29 Foreign body removal
13 ESD and EMR 30 Obesity treatment
14 New minimally invasive endoscopy 31 NOTES
15 EUS 32 POEM
16 EUS and FNA technique 33 Other
17 ERCP and ERCP-related technique    

●Poster Presentation
[General Poster Size]
• The poster panel size is W90 cm × H160 cm.
• The Secretariat will attach a 20 cm × 20 cm abstract number at the upper left corner.
• Please prepare your title in the size of H20 cm × W70 cm.


6. Instruction for Preparing Abstract

Abstracts should be prepared in the following manners:

[Terminology]
Please refer to the JGES Glossary and use the appropriate terminology.
If you are a member of JGES, the 5th edition of the Glossary of Gastrointestinal Endoscopy is available.
※Member’s number and password are required to review.

[Number of Authors]
◯ Theme Sessions: A maximum of 3 authors (presenting author + up to 2 co-authors).
Please note that if your abstract is accepted for a Theme Session, only up to 2 co-authors will be listed in the published abstract.

◯ General Sessions: A maximum of 20 authors (presenting author + co-authors).

[Abstract body]
The abstract body (including title, authors’ names, affiliations, and spaces) should be within 2,170 half-width alphanumeric characters.
*In case of using pictures and/or graphs, If figures and/or tables are included, the abstract body should be within 1,410 half-width alphanumeric characters, including title, authors’ names and affiliations and spaces.
*Please refer to the registration page for further details.
Maximum number of affiliated institutions: Up to 10 institutions

7. Notification of Abstract Receipt

After completing your abstract submission, a confirmation email will be sent to you. This email will serve as the official notification of receipt.

For security reasons, we are unable to respond to inquiries regarding your password after registration. Please make sure to record both your registration number and the issued password carefully.

If you lose your password, you must resubmit your abstract, as the previous submission cannot be retrieved. Should you wish to have the earlier submission deleted, please contact the Secretariat at: 111jges-endai@convention-plus.com.

8. Notification of Abstract Acceptance

Notification of acceptance or rejection will be sent to the email address entered at the time of abstract submission. Please ensure that the address is entered accurately.

After registration, important announcements will also be sent by email, so please register an address that you check regularly.

*Important Notice: Once your abstract is accepted, you must complete your congress registration, including payment of the registration fee.

9. Privacy Policy

The 111JGES collects personal information such as name, contact details, and e-mail address at the time of abstract submission. This information will be used solely for inquiries from the Secretariat and for notifications regarding presentations.
Names, affiliations, abstract titles, and the text of abstracts will be used only for the purpose of publishing them on the website and in the abstract collection and will not be used for any purposes other than stated above. After the conference, we will ensure that information is protected from outside parties.

10. Abstract Submission

• This system has been tested and confirmed to work with the latest versions of Microsoft Edge, Google Chrome, Mozilla Firefox, and Safari. Please refrain from using any other browsers.
• When submitting an abstract for a Theme Session, please carefully review the session objectives described in the “Introduction” before submission.

New Submission
from September 24 (Wed), 2025, 13:00 (JST)



11. Conflict of Interest (COI) Disclosure

According to the society’s regulations, if the first author has a COI, submission of the disclosure form is mandatory. In such cases, the “COI Disclosure Form for Presenters (including co-presenters)” (Form 1) must be submitted for each abstract covering the past three years, counting back from the year prior to the invitation or abstract submission.

• Even if co-presenters have “No COI,” a disclosure form including the co-presenters must also be submitted.
• If the first author has “No COI,” then neither the first author nor the co-presenters are required to submit the form.

◯ Example
If the first author has a COI and there are four co-presenters, a total of five forms must be submitted for one abstract.

◯ Signature requirements
Signatures must be provided by one of the following methods:
• Handwritten signature
• Printed name with seal (hanko)
• Electronic signature (Adobe only)

◯ File naming
Please ensure that the file name includes the name of the declarant. There is no need to include the abstract registration number.
- Please note that if there are any deficiencies in the submitted documents, you will be required to resubmit them.
- If multiple files are uploaded, the most recent file will be considered valid.

When the first author has a COI, disclosure forms from both the first author and all co-presenters are mandatory. (e.g., If the first author has a COI and there are two co-presenters, a total of three forms must be submitted for that abstract.)

◯ Submission method
Detailed instructions will be provided to the relevant first authors along with the abstract acceptance/rejection notification.

For more information, please refer to the following website:
>> COI Japan Gastroenterological Endoscopy Society

12. JGES International Membership Benefits

JGES welcomes doctors outside Japan to become JGES Members.

- Online access to JGES official English journal “Digestive Endoscopy”
- Priority registration to Hands-on courses organized by JGES with discount (half-price) registration
- Discount (half-price) registration at the Congresses of Japan Gastroenterological Endoscopy Society
- Receive information on endoscopy live demonstration courses in Japan
- Payment for the annual membership fee via credit card（VISA, Mastercard, JCB, AMEX, or DINERS）

For more detailed information, please see the following page.
https://www.jges.net/english/membership

13. Contact Information

111JGES Congress Secretariat
c/o Convention Plus, Inc.
5F LUCID SQUARE YUSHIMA, 2-31-14 Yushima, Bunkyo-ku, Tokyo, 113-0034, Japan
TEL: +81-3-4355-1139
E-mail: 111jges-endai@convention-plus.com